Updated on 23 June 2014
Patients with refractory and tophaceous gout have currently very limited treatment options
Singapore: China based biotech firm, 3SBio, has partnered with Selecta Biosciences to license out pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.
Pegsiticase has shown the ability to efficiently reduce plasma uric acid levels in gout patients in successful US Phase 1 clinical tests. The exclusive license enables Selecta to develop pegsiticase in patients with refractory and tophaceous gout and apply its immunomodulatory Synthetic Vaccine Particle (SVP) platform to optimize the safety and efficacy profile for patients at risk of immunogenicity. SEL-212 is a novel product that combines Selecta's proprietary SVP with 3SBio's pegsiticase and is designed to be the first non-immunogenic version of uricase.
"Pegsiticase has already shown significant efficacy signals in gout patients.
We have the opportunity to develop a novel therapeutic approach with the goal of preventing the inhibitory antibodies and other complications of immunogenicity that have been a significant barrier to the widespread use of uricase-based drugs," Mr Werner Cautreels, president and chief executive officer of Selecta said.
He added, "With the combination of SVP and pegsiticase, we believe we can dramatically improve treatment for patients with refractory and tophaceous gout."
"Working with 3SBio, we have the potential to fulfill a key medical need expressed by physicians, the first non-immunogenic uricase. 3SBio's strength of enzyme manufacturing combined with Selecta's proprietary antigen-specific tolerance platform will ensure fast progress towards human proof of concept. If successful, Selecta's SVP platform may unlock the full therapeutic potential of many other biologic therapies adversely affected by immunogenicity," he explained.